𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A pilot trial of quetiapine for the treatment of patients with delirium

✍ Scribed by Chi-Un Pae; Soo-Jung Lee; Chang-Uk Lee; Chul Lee; In-Ho Paik

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
43 KB
Volume
19
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Twenty‐two Korean inpatients with delirium were administered prospectively a flexible dose of quetiapine. The delirium rating scale‐revised‐severity 98 (DRS‐R‐98) and clinical global impression scale‐severity (CGI‐s) scores were assessed at the time of pre‐ and post‐treatment. The DRS‐R‐98 and CGI‐s scores were significantly reduced by 57.3% and 55.1%, respectively. Quetiapine was effective and safe for the treatment of patients with delirium, and could be a useful alternative agent to classical antipsychotics in the treatment of delirium. Copyright © 2004 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Nizatidine for the treatment of patients
Nizatidine for the treatment of patients with quetiapine-induced weight gain
✍ Murad Atmaca; Murat Kuloglu; Ertan Tezcan; Bilal Ustundag; Nulufer Kilic 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 1 views

## Abstract It has been reported that nizatidine may reduce weight gain in schizophrenic patients on olanzapine treatment. Leptin has been reported to be associated with antipsychotic‐induced weight gain. Thus, the purpose of the study was to evaluate whether nizatidine might be useful for the trea

Quetiapine versus olanzapine for the tre
Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia
✍ Pinkhas Sirota; Irit Pannet; Ady Koren; Eleonora Tchernichovsky 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract Negative symptoms are considered the most debilitating and refractory aspect of schizophrenia, being associated with poor social, occupational and global outcomes. Conventional antipsychotics have limited efficacy against these symptoms and poor tolerability profiles. Atypical antipsych

A randomized, active-control, pilot tria
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease
✍ John A. Glaspy; Jaswant Sinh Jadeja; Glen Justice; Alex Fleishman; Gregory Rossi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract ## BACKGROUND Anemia in patients receiving chemotherapy can be ameliorated with recombinant human erythropoietin (rHuEPO), which is administered one to three times per week. Darbepoetin α, a new erythropoietic agent, has longer serum residence time, allowing it to be administered less

Akathisia as a side effect of antipsycho
Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease
✍ Christian Prueter; Benedikt Habermeyer; Christine Norra; Christoph M. Kosinski 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB 👁 1 views

## Abstract Due to its low profile for extrapyramidal side‐effects, quetiapine has become an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease (PD). We describe the case of a patient with PD who developed severe akathisia, a common complication

Effectiveness of antipsychotic polypharm
Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone
✍ Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Shinichiro Nakajima; Kensuk 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective To evaluate the effectiveness of antipsychotic polypharmacy in a methodologically sound manner. ## Methods In this open‐label study, 17 patients with treatment‐refractory schizophrenia, who failed to respond to a sequential monotherapy with olanzapine, quetiapine and ris